Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors

An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors

This is an open-label, multicenter, dose-escalation phase I study to assess the safety, tolerability and preliminary efficacy of KN046 in participants with all advanced solid tumors who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) or a biological effective dose (BED), to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of KN046 as a single agent in adult participants with advanced solid tumors

Study Overview

• Status: Unknown
• Conditions: Advanced Solid Tumors
• Intervention / Treatment: Drug: KN046

• Study Type: Interventional
• Enrollment (Anticipated): 21
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Jermaine Coward, A/Prof; Phone Number: +61-07-3737-4500; Email: jim.coward@gmail.com

Study Locations

• Australia
  • Queensland
    • Southport, Queensland, Australia, 4125
      • Recruiting
      • ICON Cancer Care
      • Contact: Jermaine Coward, A/Prof; Phone Number: +61-07-3737-4500; Email: jim.coward@gmail.com
      • Principal Investigator: Craig Underhill

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. The subject must sign the informed consent form prior to the conduct of any study related procedures that are required during the screening period and are not considered part of standard of care.
2. Subjects must have histologic or cytologic confirmed Advanced solid tumors.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Adequate organ function within 3 weeks prior to initial treatment.
5. Ability to comply with treatment, procedures and PK sample collection and the required study follow-up procedures.
6. Female patients and males with partners of childbearing potential should be using highly effective contraceptive measures (failure rate of less than 1% per year). Contraception should be continued for a period of 24 weeks after dosing has been completed.
7. Female patients must have a negative serum or urine pregnancy test
8. Female patients must not be breastfeeding.

Exclusion Criteria:

1. Subjects with brain metastases or leptomeningeal are excluded.
2. Concurrent enrollment in another clinical study, unless in a follow-up period or the study is an observational or non-interventional study.
3. Any kind of immunotherapy within 6 weeks of the first dose of study treatment.
4. Prior systemic cytotoxic chemotherapy, other anticancer drugs or growth factor within 28 days of the first dose of study treatment, or any investigational agents within 5 half-lives of the product.
5. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the 1st dose of study treatment, or have an anticipated need for major surgery during the study.
6. Palliative radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the 1st dose of study treatment.
7. Prior treatment or with sequential monotherapy with anti-CTLA-4 and anti-PD-1/PD-L agents.
8. Patients who have received monotherapy with PD-L1 / PD-1, CTLA4 or other antibodies and had intolerable toxicity or required steroids to manage toxicity.
9. History of autoimmune or inflammatory disorders.
10. A current or prior use of immunosuppressive medication within 14 days of the 1st dose of study treatment.
11. Suspected latent tuberculosis infection, confirmed by Mantoux test and a chest x-ray.
12. Any unresolved toxicity NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
13. Any factors that increase the risk of QT (ECG interval measured from the onset of the QRS complex to the end of the T wave) interval corrected for heart rate (QTc) prolongation or risk of arrhythmic events (e.g., heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age) or mean QTc>470 msec.
14. Positive blood screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus 1/2 antibody (HIV 1/2 Ab).
15. History of severe allergic reactions to any unknown allergens or to parenteral administered recombinant protein product.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: KN046	Drug: KN046; The modified phase I "3 + 3" study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with dose limiting toxicity (DLT)	An DLT is defined as a ≥Grade 3 drug-related adverse event occurring within the first cycle (28 days) of dosing (excluding tumor flare causing local pain at sites of known or suspected tumor, localized rash, or a transient ≤Grade 3 infusion reaction) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).	During the first cycle (4 weeks) of treatment.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with adverse events (AEs)	An AE is defined as any untoward medical occurrence in a participant administered KN046 and/or pharmaceutical product(s) temporally associated with the use of study treatment, whether or not considered related to the study treatment.	From the time of informed consent signed through 90 days after the last dose of KN046，up to 2 years.
Objective response rate (ORR)	The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.	From first dose of KN046 through 90 days after last dose of KN046, up to 2 years.
Duration of response (DoR)	Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.	up to 2 years.
Progression-free survival (PFS)	Progression-free survival is defined as the time from the start of treatment with KN046 until the first documentation of disease progression or death due to any cause, whichever occurs first.	From first dose of KN046 through 90 days after last dose of KN046, up to 2 years.
Clinical benefit rate (CBR)	Clinical benefit rate is defined as the percentage of patients who have achieved complete response (CR), partial response (PR) and stable disease (SD) to KN046 intervention.	From first dose of KN046 through 90 days after last dose of KN046, up to 2 years.
Area under the curve (AUC) of KN046	The endpoints for assessment of PK of KN046 include serum concentrations of KN046 at different timepoints after KN046 administration.	From first dose of KN046 through 90 days after last dose of KN046, up to 9 months.
Maximum observed concentration (Cmax) of KN046	The endpoints for assessment of PK of KN046 include serum concentrations of KN046 at different timepoints after KN046 administration.	From first dose of KN046 through 90 days after last dose of KN046, up to 9 months.
Minimum observed plasma concentration (Ctrough) of KN046 at steady state	The endpoints for assessment of PK of KN046 include serum concentrations of KN046 at different timepoints after KN046 administration.	From first dose of KN046 through 90 days after last dose of KN046, up to 9 months.
Number of subjects who develop detectable anti-drug antibodies (ADAs)	The immunogenicity of KN046 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).	Assessed before KN046 infusion in Cycle 1, 2, 3, 4, 5, 6 and at the mandatory Safety Follow-up Visit, maxium up to 2 years.
Number of subjects who develop detectable neutralizing ADA (NADA)	The neutralizing ADA will be assessed by summarizing the number of subjects who develop detectable neutralizing ADA .	Assessed before KN046 infusion in Cycle 1, 2, 3, 4, 5, 6 and at the mandatory Safety Follow-up Visit, maxium up to 2 years.

Collaborators and Investigators

• Sponsor: Alphamab (Australia) Co Pty Ltd.

Study record dates

Study Major Dates

• Study Start (Anticipated): May 21, 2018
• Primary Completion (Anticipated): October 30, 2019
• Study Completion (Anticipated): March 30, 2020

Study Registration Dates

• First Submitted: May 8, 2018
• First Submitted That Met QC Criteria: May 17, 2018
• First Posted (Actual): May 18, 2018

Study Record Updates

• Last Update Posted (Actual): May 22, 2018
• Last Update Submitted That Met QC Criteria: May 20, 2018
• Last Verified: May 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: KN046-AUS-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No